PALO ALTO, Calif.  , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025, from 4:00 pm ET to 5:30 pm ET.The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of ...

Kodiak Sciences (KOD) incurred a loss of $1.09 per share in the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 82 cents per share in the year-ago quarter.The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)KOD's Q1 Results in DetailResearch and development expenses were $43.6 million in the repo ...

PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025."In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing port ...